← All indications
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.
Drugs by status
Phase 4 trials (10)
Phase 3 trials (77)
- hafnium oxide
- bacampicillin
- ponatinib
- clavulanate
- nedaplatin
- xl092
- tremelimumab
- bempegaldesleukin
- oxycodone
- toripalimab
- iae0972
- prednisolone
- ak117
- ticarcillin
- gabapentin
- mrg003
- nivolumab
- isotretinoin
- asp-1929
- gemcitabine
- sct-i10
- avelumab
- bevacizumab
- epidermal growth factor
- erlotinib
- enzalutamide
- 64cu-dota-daratumumab
- lidocaine
- nimotuzumab
- cemiplimab
- +47 more
Phase 2 trials (396)
- srf114
- interleukin-12
- morphine
- anlotinib
- relatlimab
- jk08
- gimeracil
- ixabepilone
- enlonstobart
- oc-001
- nisin
- albumin (Human)
- fimaporfin
- surufatinib
- 68ga-nodaga-rgd
- mk-1775
- HPV16-E7-T512
- onc-392
- cabiralizumab
- tub-030
- trigriluzole
- gsk-2636771
- etbx-051
- rtx-224
- rm-1929
- aminolevulinic acid
- sargramostim
- alpelisib
- isa 101
- dasatinib
- +366 more
Phase 1 trials (256)
- sapropterin
- lurbinectedin
- qeq278
- fs118
- tpst-1120
- berzosertib
- sigvotatug vedotin
- bl-b16d1
- Autologous tumor vaccine
- modified vaccinia virus ankara vaccine expressing p53
- saridegib
- BI 770371
- cesium 131
- dm005
- abexinostat
- scg142 tcr-t cells
- gv20-0251
- lenalidomide
- mgc026
- f-arag
- ly4101174
- xmab20717
- xb010
- xmab23104
- sitravatinib
- nexi-003 t cells
- gallium-68-dotatate
- pf-06940434
- rndo-564
- [225]-fpi-2059
- +226 more
Other trials (36)
- varenicline
- sugammadex
- sodermix dismutase
- 131 iodine
- coffee
- pregabalin
- methadone
- 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose
- ozone
- glycerol
- netupitant
- glycopyrronium
- bupropion
- nicotine
- inulin
- polyethylene glycol
- sodium fluoride (18F)
- silver sulfadiazine
- remifentanil
- at 406
- acetylcysteine
- palonosetron
- dexmedetomidine
- selenite
- calendula
- dextrose
- panthenol
- neostigmine
- pimonidazole
- venlafaxine
- +6 more
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (56)
- Pierre Fabre
- Incyte
- Bristol-Myers Squibb
- Debiopharm
- Roche
- AstraZeneca
- Merck KGaA
- Pfizer
- Sanofi
- Ferrer Internacional S.A.
- GlaxoSmithKline
- Guangzhou Double Bioproducts Co., Ltd
- Innate Pharma
- Innogene Kalbiotech Pte. Ltd
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- MacroGenics
- Sinocelltech Ltd.
- Boehringer Ingelheim
- The Christie NHS Foundation Trust
- International Atomic Energy Agency
- National Cancer Institute (NCI)
- Aarhus University
- University of Pennsylvania
- Associazione Volontari Pazienti Oncologici
- Barretos Cancer Hospital
- Centre Jean Perrin
- Centre Leon Berard
- Cornell University
- Danish Head and Neck Cancer Group
- Grupo de Investigación Clínica en Oncología Radioterapia
- +26 more
Organization Involved with Phase 2 Indications (254)
- PPD
- Acceleron Pharma, Inc.
- Regeneron
- Seattle Genetics
- Eisai
- Takeda
- Celgene
- Millennium Pharmaceuticals
- Amgen
- Genmab
- OSI Pharmaceuticals
- Advaxis, Inc.
- Astellas
- Imclone
- Immunomedics
- Merck Serono
- Pharmacyclics
- Eli Lilly
- Exelixis
- Genentech
- MedImmune
- Plexxikon
- Aventis
- Ipsen
- AIO-Studien-gGmbH
- Novartis
- ALX Oncology
- Alkermes
- ArQule
- Bayer
- +224 more
Organization Involved with Phase 1 Indications (70)
- AbbVie
- Aceragen, Inc/
- Boston Biomedical
- Daiichi Sankyo
- Biocon Limited
- CellSight Technologies, Inc.
- Corvus Pharmaceuticals, Inc.
- CureVac AG
- Fate Therapeutics
- Galectin Therapeutics Inc.
- GW Pharmaceuticals Ltd.
- INC Research
- Merrimack Pharmaceuticals
- Mirati Therapeutics Inc.
- Moderna Therapeutics
- NantWorks
- PsiOxus Therapeutics Ltd
- Presage Biosciences
- Spring Bank Pharmaceuticals, Inc.
- Vaccinex Inc.
- VCN Biosciences, S.L.
- Vyriad, Inc.
- immatics Biotechnologies GmbH
- Forbius
- Translational Drug Development
- Baromedical Research Foundation
- British Columbia Cancer Agency
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Canadian Cancer Trials Group
- Case Western Reserve University
- +40 more
Organization Involved with Other Experimental Indications (5)